Table 4.
Oncological data for patients who were evaluated as potent preoperatively
| Variable | Bilaterally nerve spared | Unilaterally nerve spared | Partial resection of NVB |
|---|---|---|---|
| Age (range) | 59.8 (46–71) | 60.4 (53–74) | 63.5 (59–72) |
| PSA ng ml−1 (range) | 6.6 (2.7–21) | 6.6 (1.1–14) | 8.5 (3.2–17) |
| T1c tumours (%) | 30/36 (83.3%) | 11/24 (45.8%) | 10/23 (43.5%) |
| T2 tumours (%) | 6/36 (16.6%) | 13/24 (54.2%) | 11/23 (47.8%) |
| T3 tumours (%) | 0/36 | 0/24 | 2/23 (8.7%) |
| Gleason score (preoperatively) ≤ 6 | 32/36 (88.9%) | 19/24 (79.2%) | 16/23 (69.6%) |
| = 7 | 4/36 (11.1) | 3/24 (12.5%) | 6/23 (26.1%) |
| ≥ 8 | 0/36 | 2/24 (8.3%) | 1/23 (4.4%) |
| pT3 tumours (%) | 7/36 (24.1%) | 5/24 (20.8%) | 13/23 (56.5%) |
| Positive margins (%) | 7/36 (24.1%) | 4/24 (16.7%) | 4/23 (15.7%) |